Healthcare >> Analyst Interviews >> July 14, 2003
KENNETH R. NOVER, Vice President of A.G. Edwards, covers the US-based
global large-capitalization pharmaceutical companies. He also covers
specialty pharmaceutical and biotechnology stocks. He joined A.G.
Edwards in 1992. He has over 25 years of worldwide pharmaceutical and
securities industry expertise including more than 12 years of financial
and operating experience at Merck & Co., Inc., where he managed the
financial reporting, planning and analysis of Merck's international
operations. In addition, Mr. Nover served as its manager of operations
for Japan, where he conducted financial analyses to ensure corporate
goals and advised the line VP regarding acquisitions, licensing and
competitive products and markets. Immediately prior to joining A.G.
Edwards, Mr. Nover served as an analyst for a large Japanese securities
firm and the American brokerage subsidiary of a major French bank. Mr.
Nover earned a Master's degree in Business Administration with a
concentration in Finance and a Bachelor of Arts degree, cum laude, from
Rutgers University. While at Rutgers, Mr. Nover also distinguished
himself with membership in Phi Beta Kappa. Profile
year and what is your current approach for that sector?
Mr. Nover: The group has been out of favor for a good year and a
